Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Background and Aim Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptine...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Cephalalgia Reports |
| Online Access: | https://doi.org/10.1177/25158163251316809 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background and Aim Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs. |
|---|---|
| ISSN: | 2515-8163 |